



Veracyte, Inc.
Investor Relations Department
6000 Shoreline Court
Suite 300
South San Francisco, CA 94080
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: VCYT

Last Trade:	9.30
Trade Time:	4:00 PM ET Oct 20, 2017
Change:	0.11 (+1.197%)
Day Range	9.16 - 9.80
52-Week Range	5.82 - 9.71
Volume	269,438

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Veracyte is a leading genomic diagnostics company that is fundamentally improving patient care by resolving diagnostic uncertainty with evidence that is trustworthy and actionable. The company's products uniquely combine genomic technology, clinical science and machine learning to provide answers that give physicians and patients a clear path forward without risky, costly surgery that is often unnecessary. [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Oct 20, 2017

[Veracyte Announces Presentation of New Data Validating Accuracy of BRAF V600E and Parathyroid Tissue Classifiers at ATA Annual Meeting](#)

Oct 19, 2017

[Veracyte Announces New Data Demonstrating Clinical Utility of Percepta Bronchial Genomic Classifier to be Presented at CHEST Annual Meeting 2017](#)

Oct 13, 2017

[Veracyte Chairman and CEO Bonnie Anderson Receives Prestigious Innovation Award at Biomedical Engineering Society Annual Meeting](#)

Oct 5, 2017

[Veracyte Announces Data From Five Studies Validating the Next-Generation Afirma Genomic Sequencing Classifier to Be Presented at ATA 2017 Annual Meeting](#)

Sep 25, 2017

[Veracyte Announces Release of 2018 Preliminary Reimbursement Rate for Afirma Genomic Classifier Under PAMA](#)

Financials [\[View all \]](#)

[First Quarter Financial Results](#)

Mar 1, 2017

[Annual Report \(10-K\)](#)

Apr 21, 2017

[Proxy Statement \(DEF 14A\)](#)

Jul 31, 2017

[Quarterly Report \(10-Q\)](#)

May 3, 2017

[Quarterly Report \(10-Q\)](#)

Nov 3, 2016

[Quarterly Report \(10-Q\)](#)